Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

• Sponsor: Mayo Clinic (Other)
• Overall Status: Completed
• CT.gov ID: NCT01024010
• Collaborator: National Cancer Institute (NCI) (NIH)
• Enrollment: 82
• Locations: 4
• Arms: 2
• Actual Duration (Months): 90.9
• Patients Per Site: 20.5
• Patients Per Site Per Month: 0.2

Study Details

Study Description

Brief Summary

This phase II trial studies how well giving ofatumumab together with pentostatin and cyclophosphamide works in treating patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Monoclonal antibodies, such as ofatumumab, can block the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as pentostatin and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ofatumumab together with pentostatin and cyclophosphamide may be a better way to block cancer growth.

Condition or Disease	Intervention/Treatment	Phase
Chronic Lymphocytic Leukemia; Stage 0 Chronic Lymphocytic Leukemia; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma	Drug: Cyclophosphamide; Other: Laboratory Biomarker Analysis; Biological: Ofatumumab; Drug: Pentostatin	Phase 2

Detailed Description

PRIMARY OBJECTIVES:

1. Arm A: To assess the rate of complete response using pentostatin, cyclophosphamide, and ofatumumab in patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) requiring therapy.

2. Arm B: To assess the treatment-free survival rate at 18 months using pentostatin, cyclophosphamide, and ofatumumab induction therapy followed by ofatumumab consolidation in patients with previously untreated CLL or SLL requiring therapy.

SECONDARY OBJECTIVES:

1. Arm A and Arm B: To assess the rate of overall response in patients with previously untreated CLL or SLL requiring therapy and to determine the proportion of patients who achieve a minimal residual disease (MRD) negative state as assessed by flow cytometry in each arm independently.

2. Arm A and Arm B: To monitor and assess toxicity in patients with previously untreated CLL or SLL in each arm independently.

3. Arm A and Arm B: To determine the progression-free survival, treatment-free survival, and duration of response in each arm independently.

4. Arm A and Arm B: To determine if molecular prognostic parameters (zeta-chain-associated protein [ZAP]-70, cluster of differentiation [CD]38, cytogenetic abnormalities identified by fluorescence in situ hybridization [FISH], immunoglobulin heavy-chain variable-region [IgVH] mutation status, etc) relate to response to therapy in each arm independently.

5. Arm B: To assess the rate of complete response using pentostatin, cyclophosphamide, and ofatumumab induction followed by ofatumumab consolidation in patients with previously untreated CLL or SLL requiring therapy.

6. Arm B: To evaluate whether consolidation therapy with ofatumumab after pentostatin, cyclophosphamide, and ofatumumab (PCO) induction improves the depth of response.

TERTIARY OBJECTIVES:

1. Arm A and Arm B: To assess the complete and overall response as well as treatment free survival in each arm as compared to a historic control of patients treated with pentostatin, cyclophosphamide, and rituximab in an exploratory manner.

2. Arm A and Arm B: To assess the complete and overall response as well as treatment free survival of patients treated with PCO induction followed by ofatumumab consolidation (Arm B) as compared to patients treated with PCO induction who did not receive ofatumumab consolidation (Arm A) in an exploratory manner.

3. Arm A and Arm B: Assess the mechanisms of ofatumumab induced cell death and explore methods to enhance ofatumumab cytotoxicity.

OUTLINE: Patients are assigned to 1 of 2 treatment arms.

ARM A (closed to accrual as of 8/23/2011): Patients receive induction therapy comprising ofatumumab intravenously (IV) on day 1 (days 1-2 of course 1 only), pentostatin IV over 30 minutes on day 1, and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.

ARM B: Patients receive induction therapy as in Arm A. Patients then receive consolidation therapy comprising ofatumumab IV on day 1. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 90 days for 1 year.

Study Design

• Study Type: Interventional
• Actual Enrollment: 82 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase II Trial of Pentostatin, Cyclophosphamide, and Ofatumumab for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL)
• Actual Study Start Date: Mar 1, 2010
• Actual Primary Completion Date: May 1, 2013
• Actual Study Completion Date: Sep 28, 2017

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Arm A (PCO, closed to accrual as of 8/23/2011) Patients receive induction therapy comprising ofatumumab IV on day 1 (days 1-2 of course 1 only), pentostatin IV over 30 minutes on day 1, and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.	Drug: Cyclophosphamide; Given IV; Other Names: (-)-Cyclophosphamide 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate Carloxan Ciclofosfamida Ciclofosfamide Cicloxal Clafen Claphene CP monohydrate CTX CYCLO-cell Cycloblastin Cycloblastine Cyclophospham Cyclophosphamid monohydrate Cyclophosphamidum Cyclophosphan Cyclophosphane Cyclophosphanum Cyclostin Cyclostine Cytophosphan Cytophosphane Cytoxan Fosfaseron Genoxal Genuxal Ledoxina Mitoxan Neosar Revimmune Syklofosfamid WR- 138719 ; Other: Laboratory Biomarker Analysis; Correlative studies; Biological: Ofatumumab; Given IV; Other Names: Arzerra GSK1841157 HuMax-CD20 HuMax-CD20, 2F2 ; Drug: Pentostatin; Given IV; Other Names: (R)-3-(2-Deoxy-.beta.-D-erythro-pentofuranosyl)-3,6,7, 8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol 2'-Deoxycoformycin CI-825 Co-Vidarabine Covidarabine DCF Deoxycoformycin Nipent PD-81565 Pentostatine
Experimental: Arm B (PCO with ofatumumab consolidation) Patients receive induction therapy as in Arm A. Patients then receive consolidation therapy comprising ofatumumab IV on day 1. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.	Drug: Cyclophosphamide; Given IV; Other Names: (-)-Cyclophosphamide 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate Carloxan Ciclofosfamida Ciclofosfamide Cicloxal Clafen Claphene CP monohydrate CTX CYCLO-cell Cycloblastin Cycloblastine Cyclophospham Cyclophosphamid monohydrate Cyclophosphamidum Cyclophosphan Cyclophosphane Cyclophosphanum Cyclostin Cyclostine Cytophosphan Cytophosphane Cytoxan Fosfaseron Genoxal Genuxal Ledoxina Mitoxan Neosar Revimmune Syklofosfamid WR- 138719 ; Other: Laboratory Biomarker Analysis; Correlative studies; Biological: Ofatumumab; Given IV; Other Names: Arzerra GSK1841157 HuMax-CD20 HuMax-CD20, 2F2 ; Drug: Pentostatin; Given IV; Other Names: (R)-3-(2-Deoxy-.beta.-D-erythro-pentofuranosyl)-3,6,7, 8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol 2'-Deoxycoformycin CI-825 Co-Vidarabine Covidarabine DCF Deoxycoformycin Nipent PD-81565 Pentostatine

Outcome Measures

Primary Outcome Measures

1. Arm A: Percentage of Complete Responses [7 months]

   In Arm A: PCO, the primary endpoint of this trial is the percentage of complete responses. The NCI Working Group criteria was used to assess response to therapy: A Complete Response (CR) is briefly defines as the absence of lymphadenopathy, no heptomegaly nor splenomegaly, neutrophils greater than 1500/ul, platelets > 100,000/ul, hemoglobin >11.0 gm/dl, and peripheral blood lymphocytes <4000uL.

2. Arm B: Treatment-free Survival at 18 Months [18 months]

   The primary endpoint Arm B: PCO+O is treatment-free survival rate at 18 months. An event for treatment-free survival will be defined as initiation of subsequent therapy for CLL or death due to any cause. All patients meeting the eligibility criteria who have signed a consent form and have begun treatment will be evaluable for event-free survival at 18 months. The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true success proportion will be calculated.

Secondary Outcome Measures

1. Overall Response Rate [14 months]

   The overall response rate will be estimated by the total number of complete or partial responses (CCR, CR, CRi, nPR, or PR) divided by the total number of evaluable patients. Responses will be evaluated using NCI Working Group criteria. Minimum requirements for a Partial Response (PR) requires: 50% decrease in peripheral blood lymphocyte count from the baseline 50% reduction in the sum of the products of the largest measured node or nodal masses on physical examination. 50% reduction in size of liver and/or spleen 50% improvement in neutrophils, platelets and hemoglobin

2. Depth of Response After Ofatumumab Consolidation [14 months]

   The proportion of patients with an improvement in depth of response with the addition of ofatumumab consolidation after PCO induction will be estimated by the number of patients with improvement in response from the time of response evaluation at the completion of PCO to the time of response evaluation at the completion of ofatumumab consolidation divided by the total number of evaluable patients. The hierarchy for depth of response will be in the following increasing order: SD, PR, nPR, CR/CRi with MRD+, CR/CRi with MRD-. An improvement in depth of response will be defined as an improvement of at least one level in the hierarchy. Exact binomial 95% confidence intervals for the true overall improvement rate will be calculated.

3. Treatment-free Survival [up to 5 years from registration]

   Treatment-free survial is defined as the time from registration to the date of initiation of subsequent treatment for CLL or death due to any cause. The distribution of treatment-free survival will be estimated using the method of Kaplan-Meier.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Diagnosis of CLL according to the National Cancer Institute (NCI) criteria or SLL according to the World Health Organization (WHO) criteria, including previous documentation of:

• Biopsy-proven SLL

• Diagnosis of CLL according to NCI working group criteria as evidenced by all of the following:

• Peripheral blood lymphocyte count of > 5,000/mm^3 consisting of small to moderate size lymphocytes, with < 55% prolymphocytes

• Immunophenotyping consistent with CLL defined as:

• The predominant population of lymphocytes share both B-cell antigens (CD19, CD20 [typically dim expression], or CD23) as well as CD5 in the absence of other pan-T-cell markers (CD3, CD2, etc.)

• Clonality as evidenced by kappa or lambda light chain expression (typically dim immunoglobulin expression)

• Note: splenomegaly, hepatomegaly, or lymphadenopathy are not required for the diagnosis of CLL

• Before diagnosing CLL or SLL, mantle cell lymphoma must be excluded by demonstrating a negative FISH analysis for t(11;14)(immunoglobulin heavy [IgH]/cyclin D1 [CCND1]) on peripheral blood or tissue biopsy or negative immunohistochemical stains for CCND1 on involved tissue biopsy

• Patients must be previously untreated and meet at least one of the following indications for chemotherapy:

• Evidence of progressive marrow failure as manifested by the development of or worsening anemia (=< 11 g/dl) and/or thrombocytopenia (=< 100,000/mm^3) not due to autoimmune disease

• Symptomatic or progressive lymphadenopathy, splenomegaly or hepatomegaly

• One or more of the following disease-related symptoms:

• Weight loss > 10% within the previous 6 months

• Extreme fatigue attributed to CLL

• Fevers > 100.5 degree Fahrenheit for 2 weeks without evidence of infection

• Drenching night sweats without evidence of infection

• Progressive lymphocytosis due to CLL with an increase of > 50% over a two-month period or an anticipated doubling time of less than six months

• Prior chemotherapy or monoclonal antibody based therapy for treatment of CLL will be considered prior therapy; nutraceutical treatments with no established benefit in CLL (such as epigallocatechin gallate [EGCG], found in green tea or other herbal treatments) will not be considered "prior treatment"

• Marked hypogammaglobulinemia or the development of a monoclonal protein in the absence of any of the above criteria for active disease are not sufficient for protocol therapy

• Serum creatinine =< 1.5 x upper normal levels (UNL)

• Total bilirubin =< 1.5 x UNL unless due to Gilbert's disease; if total bilirubin is > 1.5 x UNL, a direct bilirubin should be performed and must be < 1.5 mg/dL for Gilbert's to be diagnosed

• Aspartate aminotransferase (AST) =< 3.0 x UNL and alanine aminotransferase (ALT) =< 3.0 x UNL (unless due to hemolysis or CLL)

• Eastern Cooperative Oncology Group (ECOG) performance status (PS): 0, 1, or 2

• Willingness to provide blood samples as required

• Able to adhere to the study visit schedule and other protocol requirements

Exclusion Criteria:

• Any of the following comorbid conditions:

• New York Heart Association Class III or IV heart disease

• Recent myocardial infarction (< 1 month)

• Uncontrolled infection

• Infection with the human immunodeficiency virus (HIV/acquired immunodeficiency syndrome [AIDS])

• Infection with known chronic, active Hepatitis C

• Positive serology for hepatitis B (HB) defined as a positive test for HB surface antigen (HBsAg); in addition, if negative for HBsAg but HB core antibody (HBcAb) positive (regardless of HBsAb status), a HB deoxyribonucleic acid (DNA) test will be performed and if positive the subject will be excluded

• Pregnant women

• Nursing women

• Men or women of childbearing potential who are unwilling to employ adequate contraception

• Other active primary malignancy requiring treatment or limiting survival to =< 2 years

• Any radiation therapy =< 4 weeks prior to registration

• Any major surgery =< 4 weeks prior to registration

• Current use of corticosteroids; EXCEPTION: low doses of steroids (< 10 mg of prednisone or equivalent dose of other steroid) used for treatment of non-hematologic medical conditions; Note: previous use of corticosteroids is allowed

• Active hemolytic anemia requiring immunosuppressive therapy or other pharmacologic treatment; patients who have a positive Coombs test but no evidence of hemolysis are NOT excluded from participation

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Mayo Clinic in Arizona	Scottsdale	Arizona	United States	85259
2	Mayo Clinic in Florida	Jacksonville	Florida	United States	32224-9980
3	Mayo Clinic	Rochester	Minnesota	United States	55905
4	Duke University Medical Center	Durham	North Carolina	United States	27710

Sponsors and Collaborators

• Mayo Clinic
• National Cancer Institute (NCI)

Investigators

• Principal Investigator: Tait Shanafelt, Mayo Clinic

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Mayo Clinic
• ClinicalTrials.gov Identifier: NCT01024010
• Other Study ID Numbers: MC0983; NCI-2009-01437; MC0983; P30CA015083
• First Posted: Dec 2, 2009
• Last Update Posted: Sep 18, 2018
• Last Verified: Sep 1, 2017

• Additional relevant MeSH terms: Lymphoma; Leukemia; Leukemia, Lymphoid; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine; Cyclophosphamide; Ofatumumab; Pentostatin; Antibodies, Monoclonal

Study Results

Participant Flow

Arm/Group Title	Arm A: PCO	Arm B: PCO +O
Arm/Group Description	Patients receive 300 mg ofatumumab IV on days 1, cycle 1 and 1000 mg ofatumumab IV on day 2 of cycle 1 and on day 1 of cycles 2-6. During cycles 1-6, patients also receive 2 mg/m^2 pentostatin IV over 30 minutes on day 1, 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 1, and 6 mg pegfilgrastim subcutaneously on day 2.	Patients receive 300 mg ofatumumab IV on day 1, cycle 1 and 1000 mg ofatumumab IV on day 2 of cycle 1 and on day 1 of cycles 2-6. During cycles1-6, patients also receive 2 mg/m^2 pentostatin IV over 30 minutes on day 1, 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 1, and 6 mg pegfilgrastim subcutaneously on day 2. For cycles 7-12, patients receive 1000 mg ofatumumab IV on day 1.
Period Title: Overall Study
STARTED	48	34
COMPLETED	48	34
NOT COMPLETED	0	0

Baseline Characteristics

Arm/Group Title	Arm A: PCO	Arm B: PCO +O	Total
Arm/Group Description	Patients receive 300 mg ofatumumab IV on days 1, cycle 1 and 1000 mg ofatumumab IV on day 2 of cycle 1 and on day 1 of cycles 2-6. During cycles 1-6, patients also receive 2 mg/m^2 pentostatin IV over 30 minutes on day 1, 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 1, and 6 mg pegfilgrastim subcutaneously on day 2.	Patients receive 300 mg ofatumumab IV on days 1, cycle 1 and 1000 mg ofatumumab IV on day 2 of cycle 1 and on day 1 of cycles 2-6. During cycles1-6, patients also receive 2 mg/m^2 pentostatin IV over 30 minutes on day 1, 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 1, and 6 mg pegfilgrastim subcutaneously on day 2. For cycles 7-12, patients receive 1000 mg ofatumumab IV on day 1.	Total of all reporting groups
Overall Participants	48	34	82
Age (years) [Median (Full Range) ]
Median (Full Range) [years]	65	59	63
Sex: Female, Male (Count of Participants)
Female	14 29.2%	5 14.7%	19 23.2%
Male	34 70.8%	29 85.3%	63 76.8%
Region of Enrollment (participants) [Number]
United States	48 100%	34 100%	82 100%

Outcome Measures

1. Primary Outcome

Title	Arm A: Percentage of Complete Responses
Description	In Arm A: PCO, the primary endpoint of this trial is the percentage of complete responses. The NCI Working Group criteria was used to assess response to therapy: A Complete Response (CR) is briefly defines as the absence of lymphadenopathy, no heptomegaly nor splenomegaly, neutrophils greater than 1500/ul, platelets > 100,000/ul, hemoglobin >11.0 gm/dl, and peripheral blood lymphocytes <4000uL.
Time Frame	7 months

Outcome Measure Data

Analysis Population Description

All patients that began Arm A protocol treatment were included in this analysis.

Arm/Group Title	Arm A: PCO
Arm/Group Description	Patients receive 300 mg ofatumumab IV on days 1, cycle 1 and 1000 mg ofatumumab IV on day 2 of cycle 1 and on day 1 of cycles 2-6. During cycles 1-6, patients also receive 2 mg/m^2 pentostatin IV over 30 minutes on day 1, 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 1, and 6 mg pegfilgrastim subcutaneously on day 2.
Measure Participants	48
Number (95% Confidence Interval) [percentage of participants]	46 95.8%

2. Primary Outcome

Title	Arm B: Treatment-free Survival at 18 Months
Description	The primary endpoint Arm B: PCO+O is treatment-free survival rate at 18 months. An event for treatment-free survival will be defined as initiation of subsequent therapy for CLL or death due to any cause. All patients meeting the eligibility criteria who have signed a consent form and have begun treatment will be evaluable for event-free survival at 18 months. The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true success proportion will be calculated.
Time Frame	18 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Arm A: PCO	Arm B: PCO +O
Arm/Group Description	Patients receive 300 mg ofatumumab IV on days 1, cycle 1 and 1000 mg ofatumumab IV on day 2 of cycle 1 and on day 1 of cycles 2-6. During cycles 1-6, patients also receive 2 mg/m^2 pentostatin IV over 30 minutes on day 1, 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 1, and 6 mg pegfilgrastim subcutaneously on day 2.	Patients receive 300 mg ofatumumab IV on days 1, cycle 1 and 1000 mg ofatumumab IV on day 2 of cycle 1 and on day 1 of cycles 2-6. During cycles1-6, patients also receive 2 mg/m^2 pentostatin IV over 30 minutes on day 1, 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 1, and 6 mg pegfilgrastim subcutaneously on day 2. For cycles 7-12, patients receive 1000 mg ofatumumab IV on day 1.
Measure Participants	48	34
Number (95% Confidence Interval) [percentage of participants]	87.5 182.3%	94.1 276.8%

3. Secondary Outcome

Title	Overall Response Rate
Description	The overall response rate will be estimated by the total number of complete or partial responses (CCR, CR, CRi, nPR, or PR) divided by the total number of evaluable patients. Responses will be evaluated using NCI Working Group criteria. Minimum requirements for a Partial Response (PR) requires: 50% decrease in peripheral blood lymphocyte count from the baseline 50% reduction in the sum of the products of the largest measured node or nodal masses on physical examination. 50% reduction in size of liver and/or spleen 50% improvement in neutrophils, platelets and hemoglobin
Time Frame	14 months

Outcome Measure Data

Analysis Population Description

All patients were evaluable for this endpoint.

Arm/Group Title	Arm A: PCO	Arm B: PCO +O
Arm/Group Description	Patients receive 300 mg ofatumumab IV on days 1, cycle 1 and 1000 mg ofatumumab IV on day 2 of cycle 1 and on day 1 of cycles 2-6. During cycles 1-6, patients also receive 2 mg/m^2 pentostatin IV over 30 minutes on day 1, 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 1, and 6 mg pegfilgrastim subcutaneously on day 2.	Patients receive 300 mg ofatumumab IV on days 1, cycle 1 and 1000 mg ofatumumab IV on day 2 of cycle 1 and on day 1 of cycles 2-6. During cycles1-6, patients also receive 2 mg/m^2 pentostatin IV over 30 minutes on day 1, 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 1, and 6 mg pegfilgrastim subcutaneously on day 2. For cycles 7-12, patients receive 1000 mg ofatumumab IV on day 1.
Measure Participants	48	34
Number (95% Confidence Interval) [percentage of participants]	96 200%	97 285.3%

4. Secondary Outcome

Title	Depth of Response After Ofatumumab Consolidation
Description	The proportion of patients with an improvement in depth of response with the addition of ofatumumab consolidation after PCO induction will be estimated by the number of patients with improvement in response from the time of response evaluation at the completion of PCO to the time of response evaluation at the completion of ofatumumab consolidation divided by the total number of evaluable patients. The hierarchy for depth of response will be in the following increasing order: SD, PR, nPR, CR/CRi with MRD+, CR/CRi with MRD-. An improvement in depth of response will be defined as an improvement of at least one level in the hierarchy. Exact binomial 95% confidence intervals for the true overall improvement rate will be calculated.
Time Frame	14 months

Outcome Measure Data

Analysis Population Description

Thirty-one out of the 34 patients registered to Arm B: PCO+O began consolidation, 28 were evaluated for response at the end of consolidation treatment (3 patients did not return for response evaluation at the end of treatment).

Arm/Group Title	Arm A: PCO	Arm B: PCO +O
Arm/Group Description	Patients receive 300 mg ofatumumab IV on days 1, cycle 1 and 1000 mg ofatumumab IV on day 2 of cycle 1 and on day 1 of cycles 2-6. During cycles 1-6, patients also receive 2 mg/m^2 pentostatin IV over 30 minutes on day 1, 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 1, and 6 mg pegfilgrastim subcutaneously on day 2.	Patients receive 300 mg ofatumumab IV on days 1, cycle 1 and 1000 mg ofatumumab IV on day 2 of cycle 1 and on day 1 of cycles 2-6. During cycles1-6, patients also receive 2 mg/m^2 pentostatin IV over 30 minutes on day 1, 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 1, and 6 mg pegfilgrastim subcutaneously on day 2. For cycles 7-12, patients receive 1000 mg ofatumumab IV on day 1.
Measure Participants	0	28
Number (95% Confidence Interval) [percentage of participants]	25 52.1%

5. Secondary Outcome

Title	Treatment-free Survival
Description	Treatment-free survial is defined as the time from registration to the date of initiation of subsequent treatment for CLL or death due to any cause. The distribution of treatment-free survival will be estimated using the method of Kaplan-Meier.
Time Frame	up to 5 years from registration

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Arm A: PCO	Arm B: PCO +O
Arm/Group Description	Patients receive 300 mg ofatumumab IV on days 1, cycle 1 and 1000 mg ofatumumab IV on day 2 of cycle 1 and on day 1 of cycles 2-6. During cycles 1-6, patients also receive 2 mg/m^2 pentostatin IV over 30 minutes on day 1, 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 1, and 6 mg pegfilgrastim subcutaneously on day 2.	Patients receive 300 mg ofatumumab IV on days 1, cycle 1 and 1000 mg ofatumumab IV on day 2 of cycle 1 and on day 1 of cycles 2-6. During cycles1-6, patients also receive 2 mg/m^2 pentostatin IV over 30 minutes on day 1, 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 1, and 6 mg pegfilgrastim subcutaneously on day 2. For cycles 7-12, patients receive 1000 mg ofatumumab IV on day 1.
Measure Participants	48	34
Median (95% Confidence Interval) [months]	56.6	NA

Adverse Events

Arm/Group Title	Arm A: PCO		Arm B: PCO +O
Arm/Group Description	Patients receive 300 mg ofatumumab IV on days 1, cycle 1 and 1000 mg ofatumumab IV on day 2 of cycle 1 and on day 1 of cycles 2-6. During cycles 1-6, patients also receive 2 mg/m^2 pentostatin IV over 30 minutes on day 1, 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 1, and 6 mg pegfilgrastim subcutaneously on day 2.		Patients receive 300 mg ofatumumab IV on days 1, cycle 1 and 1000 mg ofatumumab IV on day 2 of cycle 1 and on day 1 of cycles 2-6. During cycles1-6, patients also receive 2 mg/m^2 pentostatin IV over 30 minutes on day 1, 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 1, and 6 mg pegfilgrastim subcutaneously on day 2. For cycles 7-12, patients receive 1000 mg ofatumumab IV on day 1.
All Cause Mortality
	Arm A: PCO		Arm B: PCO +O
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	/ (NaN)		/ (NaN)
Serious Adverse Events
	Arm A: PCO		Arm B: PCO +O
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	10/48 (20.8%)		6/34 (17.6%)
Blood and lymphatic system disorders
Febrile neutropenia	1/48 (2.1%)	1	0/34 (0%)	0
Hemolysis	2/48 (4.2%)	2	0/34 (0%)	0
Cardiac disorders
Mobitz (type) II atrioventricular block	1/48 (2.1%)	1	0/34 (0%)	0
Gastrointestinal disorders
Abdominal pain	1/48 (2.1%)	2	0/34 (0%)	0
Nausea	1/48 (2.1%)	1	0/34 (0%)	0
General disorders
Death NOS	1/48 (2.1%)	1	0/34 (0%)	0
Fatigue	1/48 (2.1%)	1	1/34 (2.9%)	1
Immune system disorders
Allergic reaction	0/48 (0%)	0	1/34 (2.9%)	1
Infections and infestations
Anorectal infection	0/48 (0%)	0	1/34 (2.9%)	1
Infections and infestations - Other, specify	2/48 (4.2%)	2	0/34 (0%)	0
Lung infection	1/48 (2.1%)	1	0/34 (0%)	0
Sepsis	1/48 (2.1%)	1	0/34 (0%)	0
Skin infection	0/48 (0%)	0	1/34 (2.9%)	1
Investigations
Neutrophil count decreased	1/48 (2.1%)	1	0/34 (0%)	0
Platelet count decreased	1/48 (2.1%)	1	0/34 (0%)	0
White blood cell decreased	1/48 (2.1%)	1	0/34 (0%)	0
Metabolism and nutrition disorders
Dehydration	0/48 (0%)	0	1/34 (2.9%)	1
Hyperglycemia	0/48 (0%)	0	1/34 (2.9%)	2
Musculoskeletal and connective tissue disorders
Arthralgia	1/48 (2.1%)	1	0/34 (0%)	0
Nervous system disorders
Headache	1/48 (2.1%)	1	0/34 (0%)	0
Syncope	0/48 (0%)	0	1/34 (2.9%)	1
Respiratory, thoracic and mediastinal disorders
Pneumonitis	0/48 (0%)	0	1/34 (2.9%)	1
Respiratory failure	1/48 (2.1%)	1	0/34 (0%)	0
Skin and subcutaneous tissue disorders
Rash maculo-papular	1/48 (2.1%)	1	0/34 (0%)	0
Vascular disorders
Hypotension	0/48 (0%)	0	1/34 (2.9%)	1
Other (Not Including Serious) Adverse Events
	Arm A: PCO		Arm B: PCO +O
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	48/48 (100%)		34/34 (100%)
Blood and lymphatic system disorders
Anemia	40/48 (83.3%)	179	32/34 (94.1%)	183
Blood and lymphatic system disorders - Other, specify	0/48 (0%)	0	2/34 (5.9%)	2
Febrile neutropenia	1/48 (2.1%)	1	0/34 (0%)	0
Hemolysis	0/48 (0%)	0	1/34 (2.9%)	1
Endocrine disorders
Hypothyroidism	0/48 (0%)	0	1/34 (2.9%)	1
Gastrointestinal disorders
Bloating	1/48 (2.1%)	1	0/34 (0%)	0
Constipation	1/48 (2.1%)	1	0/34 (0%)	0
Diarrhea	1/48 (2.1%)	1	1/34 (2.9%)	2
Intra-abdominal hemorrhage	1/48 (2.1%)	1	0/34 (0%)	0
Nausea	18/48 (37.5%)	29	5/34 (14.7%)	10
Vomiting	6/48 (12.5%)	10	2/34 (5.9%)	6
General disorders
Chills	3/48 (6.3%)	4	1/34 (2.9%)	1
Fatigue	13/48 (27.1%)	25	6/34 (17.6%)	13
Fever	13/48 (27.1%)	16	12/34 (35.3%)	15
General disorders and administration site conditions - Other, specify	1/48 (2.1%)	1	0/34 (0%)	0
Infusion related reaction	1/48 (2.1%)	1	3/34 (8.8%)	3
Immune system disorders
Allergic reaction	0/48 (0%)	0	3/34 (8.8%)	7
Cytokine release syndrome	0/48 (0%)	0	1/34 (2.9%)	2
Infections and infestations
Anorectal infection	0/48 (0%)	0	2/34 (5.9%)	2
Lung infection	7/48 (14.6%)	9	8/34 (23.5%)	12
Mucosal infection	0/48 (0%)	0	1/34 (2.9%)	1
Peripheral nerve infection	1/48 (2.1%)	1	0/34 (0%)	0
Sepsis	0/48 (0%)	0	1/34 (2.9%)	1
Sinusitis	1/48 (2.1%)	1	1/34 (2.9%)	1
Skin infection	2/48 (4.2%)	2	2/34 (5.9%)	2
Upper respiratory infection	16/48 (33.3%)	23	19/34 (55.9%)	40
Urinary tract infection	2/48 (4.2%)	2	0/34 (0%)	0
Investigations
Alanine aminotransferase increased	1/48 (2.1%)	1	0/34 (0%)	0
Creatinine increased	1/48 (2.1%)	1	0/34 (0%)	0
INR increased	0/48 (0%)	0	1/34 (2.9%)	1
Lymphocyte count decreased	0/48 (0%)	0	18/34 (52.9%)	118
Lymphocyte count increased	0/48 (0%)	0	1/34 (2.9%)	1
Neutrophil count decreased	23/48 (47.9%)	55	26/34 (76.5%)	96
Platelet count decreased	33/48 (68.8%)	205	30/34 (88.2%)	248
Weight loss	2/48 (4.2%)	2	0/34 (0%)	0
White blood cell decreased	27/48 (56.3%)	70	28/34 (82.4%)	150
Metabolism and nutrition disorders
Anorexia	2/48 (4.2%)	2	1/34 (2.9%)	1
Hypocalcemia	0/48 (0%)	0	1/34 (2.9%)	1
Musculoskeletal and connective tissue disorders
Arthralgia	1/48 (2.1%)	2	0/34 (0%)	0
Bone pain	2/48 (4.2%)	2	0/34 (0%)	0
Flank pain	1/48 (2.1%)	1	0/34 (0%)	0
Myalgia	1/48 (2.1%)	1	0/34 (0%)	0
Nervous system disorders
Dysgeusia	1/48 (2.1%)	1	0/34 (0%)	0
Headache	2/48 (4.2%)	2	0/34 (0%)	0
Psychiatric disorders
Confusion	1/48 (2.1%)	1	0/34 (0%)	0
Depression	0/48 (0%)	0	1/34 (2.9%)	1
Insomnia	2/48 (4.2%)	2	0/34 (0%)	0
Respiratory, thoracic and mediastinal disorders
Bronchospasm	2/48 (4.2%)	3	0/34 (0%)	0
Cough	2/48 (4.2%)	2	2/34 (5.9%)	3
Dyspnea	2/48 (4.2%)	3	1/34 (2.9%)	1
Pleural effusion	1/48 (2.1%)	1	0/34 (0%)	0
Pneumonitis	0/48 (0%)	0	2/34 (5.9%)	2
Respiratory, thoracic and mediastinal disorders - Other, specify	0/48 (0%)	0	1/34 (2.9%)	1
Sinus disorder	1/48 (2.1%)	1	0/34 (0%)	0
Skin and subcutaneous tissue disorders
Pruritus	3/48 (6.3%)	4	1/34 (2.9%)	1
Rash acneiform	0/48 (0%)	0	1/34 (2.9%)	1
Rash maculo-papular	7/48 (14.6%)	8	4/34 (11.8%)	4
Skin and subcutaneous tissue disorders - Other, specify	1/48 (2.1%)	1	0/34 (0%)	0
Urticaria	5/48 (10.4%)	6	2/34 (5.9%)	2
Surgical and medical procedures
Surgical and medical procedures - Other, specify	0/48 (0%)	0	1/34 (2.9%)	1
Vascular disorders
Hypertension	1/48 (2.1%)	1	1/34 (2.9%)	1
Lymphedema	1/48 (2.1%)	1	0/34 (0%)	0

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.